Figure 2 Lifelong influences on the gut microbiome from

Slides:

Advertisements

Similar presentations

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Advertisements

Figure 3 Low-grade inflammation in FGID

Figure 4 The gut microbiota directly influences T-cell differentiation

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Interactions between adipose, the microbiome and kidney

Figure 1 Contribution of the gut microbiota

Figure 4 Activation of clopidogrel via cytochrome P450

Figure 2 Proinflammatory mechanisms in CKD

Figure 5 Therapeutic paradigms for interfering with the brain–gut axis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Gut microorganisms at the intersection of several diseases

Figure 5 Lipid droplet consumption

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 The microbiome–gut–brain axis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Biosimilar development process

Figure 3 The 'leaky gut' hypothesis

Figure 2 Effect of PPIs on gastric physiology

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Schematic outlining the results of Buffington et al.

Figure 6 Combination therapy for HCC

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.

Figure 1 Definition and concept of ACLF

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Cardiol. doi: /nrcardio

to the liver and promote patient-derived xenograft tumour growth

Figure 7 Example colonic high-resolution manometry

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Environmental factors contributing to IBD pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.

Figure 2 13C-octanoic acid gastric emptying breath test

Figure 1 Median coverage and distribution by

Figure 2 A model for the future analysis

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 The gut–liver relationship in PSC

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Volume 139, Issue 6, Pages (December 2010)

Figure 1 Brain–gut axis Brain–gut axis. Schematic of the brain–gut axis, including inputs from the gut microbiota, the ENS, the immune system and the external.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 The current model of the pathogenesis of SLE

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Assessment of colonic transit time with radiopaque markers

Figure 2 New therapeutic approaches in IBD with their specific targets

Figure 5 Systems biological model of IBS

Figure 5 PPIs and adverse events with proven and unproven causality

Figure 4 Local species pools that contribute to the

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 New therapeutic approaches in IBD therapy based on blockade of T-cell homing and retention Figure 1 | New therapeutic approaches in IBD therapy.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 NAFLD pathogenesis

Figure 1 Colonic inflammation in IBD and link to the gut microbiota

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Classifications and appearance of CCAs

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Presentation transcript:

Figure 2 Lifelong influences on the gut microbiome from conception to adult life lead to dysbiosis and development of IBD Figure 2 | Lifelong influences on the gut microbiome from conception to adult life lead to dysbiosis and development of IBD. The gut microbiome is susceptible to the influence of host genetics and environmental influences throughout childhood and adult life. The resultant alterations in taxonomic composition and function contribute to the development of intestinal inflammation in IBD. Ananthakrishnan, A. N. et al. (2017) Environmental triggers in IBD: a review of progress and evidence Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2017.136